NCT06723886
Antidiabetic Effect of Olive Pomace Oil
Recruiting · Not Applicable · Instituto de Ciencia y Tecnología de Alimentos y Nutrición · registry updated 2024-12-11
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This clinical trial aims at assessing whether consumption of olive pomace oil in the diet may benefit persons with type 2 diabetes mellitus or persons at risk of developing the disease (prediabetic persons). The main questions the study aims to answer are: * May olive pomace oil prevent a high increase of blood glucose levels when consumed in a meal together with carbohydrates in diabetic/prediabetic patients? * May olive pomace oil decrease fasting blood glucose levels of diabetic/prediabetic patients after consuming it daily? * May daily consumption of olive pomace oil improve glucose homeostasis and other alterations like elevated blood lipids or inflammation, which also affect persons with diabetes or prediabetes? Researchers will compare the effect of consuming olive pomace oil to the effects of a comparison oil (high-oleic acid sunflower oil). Participants will: In different days, they will consume white bread alone or the oils (olive pomace oil, high-oleic acid sunflower oil or extra virgin olive oil) spread on white bread and blood will be collected at different times during 2 h....
Inclusion
- Fasting blood glucose between 100-126 mg/dL and/or
- Glycated haemoglobin (HbA1c) between 5.7-6.4% and/or
- Diabetic persons with Fasting blood glucose \>126 mg/dL and/or
- Diabetic persons with Glycated haemoglobin (HbA1c) \> 6.4%
Exclusion
- Kidney or liver diseases
- Gastrointestinal diseases (irritable bowel syndrome, Crohn disease, chronic bowel inflammation)
- Food allergies/intolerances
- Vegetarians/vegans
- Pregnant or lactating women
- On prescription drugs other than for hypertension/thyroid/dyslipidemia/glucose control, or changes in dosage in the last 3 months